Investment
Features
FeesSafety
Academy
More
Pluang+

Lighter launches 15-minute binary options on Bitcoin and Ether with fixed payouts in USDC

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Lighter launches 15-minute binary options on Bitcoin and Ether with fixed payouts in USDC

Lighter's Core exchange introduced 15-minute binary options contracts tied to Bitcoin and Ether prices, allowing traders to bet on short-term price movements with fixed payouts in USDC. Traders choose whether prices will go up or down within each 15-minute window, with winning contracts paying 1 USDC and losing contracts paying nothing. These contracts require full funding in USDC, have no leverage or liquidation risks, and support market and limit orders. The platform is not available to U.S. users, and Lighter plans to expand its options offerings beyond these binary contracts in the future.

Lighter's launch of 15-minute Bitcoin and Ether binary options is noted here with Pluang's market snapshot as of Oct 20, 2026 07:21 WIB: Among 50 major cryptocurrencies priced on Pluang, 32 rose and 17 fell today. Notable movers include ZIL at Rp39 with a -2.43% change and 42% sell order activity, COMP at Rp386.125 with a +2.32% change and 99% buy order activity, and UNI at Rp131.211 with a +2.18% change and 66% buy order activity. The highest buy order activity was 99% for COMP.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App